Figure 1.

Untargeted proteomics revealed 16 biomarker candidates that differentiate nonsurvivors and survivors. Day 1 serum samples from survivors (n = 10) and nonsurvivors (n = 10) of acetaminophen-induced acute liver failure (ALF) and healthy controls (n = 10) were subjected to untargeted proteomics. A, Volcano plot displaying results for ALF survivors versus volunteer controls. B, Volcano plot displaying the 13 proteins that were ≥ 4-fold elevated in ALF survivors versus control and ≥ 4-fold further elevated in nonsurvivors versus survivors and the 3 proteins that were ≥ 4-fold decreased in ALF survivors versus control and ≥ 4-fold further decreased in nonsurvivors versus survivors.